Research institution
Abramson Cancer Center at Penn Medicine Clinical Trials
Studies where Abramson Cancer Center at Penn Medicine is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 87Ovarian Cancer
Peer Ambassador in Gyn Onc Trials
The goal of this study is to learn if peer ambassador support will increase clinical trial enrollment in patients with ovarian cancer.
- Trial name
- NCT07915336
- Testing
- Mentee encounters
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer, BRCA Mutation
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection…
- Trial name
- PROMISE (NCT06436248)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07059611
- Testing
- RP2, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Genetic Predisposition to Cancer
Breast Cancer Risk Assessment and Management Program
The objective of this project is to assess the implementation of evidence-based, digital tools to improve breast cancer risk assessment and related primary cancer prevention services for those at high risk for developing breast…
- Trial name
- RAMP-BC (NCT07911592)
- Testing
- Patient nudge via text message, Patient nudge via phone call
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC)
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave…
- Trial name
- NCT07807475
- Testing
- Hyperpolarized 1-13C -Pyruvate
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gynecologic Cancer Survivors
Developing a Gynecologic Cancer Health Promotion Community Engagement Program
The goal of this observational study is to learn about the communication systems of gynecologic cancer survivors by conducting focus groups and disseminating a survey.
- Trial name
- NCT07910162
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Malignant Neoplastic Disease (Disorder)
Saruparib in HRDsig+ Solid Tumors
The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational…
- Trial name
- NCT07832630
- Testing
- Saruparib, FoundationOne®CDx
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Sarcoma Metastatic
Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients
Subjects will undergo infusion of 5 mg/kg indocyanine green, ICG ("TumorGlow") intravenously up to 5-days prior to surgery. Then, during the surgical procedure the next day, the subjects will undergo standard-of-care surgery.
- Trial name
- TumorGlow (NCT07658768)
- Testing
- ICG INFUSION 5MG/KG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer Metastatic
FTT PET/CT in Metastatic Prostate Cancer
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer.
- Trial name
- NCT05242744
- Testing
- [18F]FluorThanatrace
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat…
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV Associated Cancers
- Trial name
- NCT07578467
- Testing
- ATRN-119, Stereotactic Body Radiation Therapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Completed, with results posted
All 80HIV Infections, Smoking Cessation
BAPS in Botswana: The Thotloetso Trial
The main purpose of this research study is to compare traditional behavioral smoking cessation therapy with a different type of behavioral therapy-known as behavioral activation problem solving (BAPS)-for smoking cessation.
- Conditions
- HIV Infections, Smoking Cessation, Smoking
- Trial name
- BOTS (NCT04532970)
- Testing
- Cessation Counseling
- Where
- Botswana
- Volunteers
- 651 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts
The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this…
- Trial name
- NCT05787249
- Testing
- Patient nudge, Provider nudge
- Where
- United States
- Volunteers
- 1,358 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Increasing Screening for Cancer Using EHR-Nudges
In this study, personalized nudges to clinicians and patients will be evaluated to help increase breast cancer screening rates in accordance with USPSTF guidelines among women with a primary care visit, with a particular emphasis…
- Trial name
- I-SCREEN (NCT06177795)
- Testing
- Post-visit patient text messaging, Default pended order, High risk bidirectional post-visit text messaging
- Where
- 2 sites in United States
- Volunteers
- 21,123 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer
Virtual Reality to Promote Relaxation Prior to Simulation
The purpose of this study is to assess the feasibility of a pre-simulation virtual reality (VR) platform designed to promote relaxation for cancer patients planned for radiation therapy (RT).
- Trial name
- NCT06318338
- Testing
- Virtual Reality Program
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine